Keywords: fda, accepts, filing, nda, fixed-dose, loratadine/montelukast, combo
US FDA accepts for filing NDA for fixed-dose loratadine/montelukast combo pill
Article | 03 September 2007
Schering-Plough and Merck Pharmaceuticals, a unit of fellow US drug major Merck & Co, say that the New Drug Application filing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
